Literature DB >> 11568589

Role of clonazepam in the treatment of idiopathic downbeat nystagmus.

Y H Young1, T W Huang.   

Abstract

OBJECTIVE/HYPOTHESIS: Downbeat nystagmus is defined as spontaneous nystagmus present with fixation in the primary position or lateral gaze. Those who have downbeat nystagmus but negative magnetic resonance imaging results are termed as idiopathic. Patients with idiopathic downbeat nystagmus, although unconcerned with their etiology, have visual symptoms such as oscillopsia, diplopia, or blurred vision. The purpose of this study is to evaluate the efficacy of clonazepam in treating idiopathic downbeat nystagmus.
METHODS: Patients with downbeat nystagmus were rechecked by electronystagmography (ENG); then 0.5 mg clonazepam was administered orally. One hour later, follow-up ENG was performed again to evaluate the evolution of the downbeat nystagmus. If the test was effective, then 1.0 mg clonazepam twice daily was administered to the patients.
RESULTS: Seven cases had downbeat nystagmus, including idiopathic in five, cerebellar degeneration in one, and cerebellopontine angle tumor in one. The efficacy rate for the clonazepam test was 100% in five cases of idiopathic downbeat nystagmus, whereas it was ineffective in the case of cerebellar degeneration. After long-term therapy with clonazepam, all patients with idiopathic downbeat nystagmus experienced elimination of oscillopsia, relief of diplopia, and improvement of visual acuity. Although temporary relief of downbeat nystagmus was observed 1 hour after the clonazepam test, downbeat nystagmus was not eliminated permanently.
CONCLUSION: We recommend long-term therapy by clonazepam with a dosage of 1.0 mg twice daily in cases of idiopathic downbeat nystagmus. Reducing the downbeat nystagmus as well as eliminating the oscillopsia can be anticipated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568589     DOI: 10.1097/00005537-200108000-00029

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  11 in total

1.  Treatment of nystagmus.

Authors:  Matthew J Thurtell; R John Leigh
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

2.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 3.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 4.  [Pharmacotherapy of central oculomotor disorders].

Authors:  R Kalla; R Spiegel; J Wagner; N Rettinger; K Jahn; M Strupp
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

Review 5.  Treatment of Visual Disorders in Parkinson Disease.

Authors:  Joseph Savitt; Michaela Mathews
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

6.  Neuro-ophthalmology of type 1 Chiari malformation.

Authors:  Aasef G Shaikh; Fatema F Ghasia
Journal:  Expert Rev Ophthalmol       Date:  2015-06-23

7.  Current Treatment of Nystagmus.

Authors:  Janet C Rucker
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

8.  Eye disorders in patients with multiple sclerosis: natural history and management.

Authors:  Jennifer Graves; Laura J Balcer
Journal:  Clin Ophthalmol       Date:  2010-12-06

Review 9.  Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.

Authors:  Michael Strupp; Matthew J Thurtell; Aasef G Shaikh; Thomas Brandt; David S Zee; R John Leigh
Journal:  J Neurol       Date:  2011-04-02       Impact factor: 4.849

10.  Transcranial magnetic stimulation for diplopia in a patient with spinocerebellar ataxia type 6: a case report.

Authors:  Kentaro Kawamura; Seiji Etoh; Megumi Shimodozono
Journal:  Cerebellum Ataxias       Date:  2018-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.